Cingulate's Shares Rise After $5 Million Capital Raise

MT Newswires Live01:30

Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.

The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.

Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.

Price: 4.94, Change: +0.84, Percent Change: +20.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493019793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-24 01:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493019793","market":"sg","top_or_hot":-1,"title":"Cingulate's Shares Rise After $5 Million Capital Raise","media":"MT Newswires Live","content":"<html><body><p> Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.</p><p>The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.</p><p>Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.</p><p>Price: 4.94, Change: +0.84, Percent Change: +20.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cingulate's Shares Rise After $5 Million Capital Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCingulate's Shares Rise After $5 Million Capital Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 01:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.The transaction involved a non-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493019793","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493019793","pubTimestamp":1734975045,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cingulate's  shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.Price: 4.94, Change: +0.84, Percent Change: +20.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CING":"CINGULATE INC."},"translate_title":"融资500万美元后Cingulate股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CING":1},"content_text":"Cingulate's (CING) shares rose nearly 19% in recent Monday trading after the company said it raised $5 million through a financing deal with an accredited investor.The transaction involved a non-convertible, unsecured promissory note for nearly $5.5 million, with a 9% annual interest rate and an 18-month maturity, the company said.Net proceeds will be used for working capital and general corporate purposes, the company said, adding that this capital will support clinical, manufacturing, regulatory activities, and operating costs into Q4 2025. The company aims to file the new drug application for potential approval of CTx-1301 by mid-2025.Price: 4.94, Change: +0.84, Percent Change: +20.37","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493019793"}